Just received a research report from canary on RNV
Probably on their website if you want to look for it - -key extract was
The company commenced trading on the ASX on 26 November 2024 following a heavily oversubscribed initial public offering, which raised the maximum amount of A$7 million (before costs).
We believe ReNerve represents an outstanding opportunity to invest in a unique Australian company which is positioning itself in the global Peripheral Neve Injury (PNI) repair market.
The initial focus of ReNerve is to expand sales of its NervAlign® Nerve Cuff product in the core US market while developing its Nerve Conduit and Nerve Guide Matrix products.
Our intrinsic valuation per share based on detailed modelling of the company is $0.365 per share compared to yesterday’s closing price of $0.135c.
DYOR and GLTAH
RNV Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)